

## GENERAL POLICIES GOVERNING THE BRAUSE FAMILY INITIATIVE FOR QUALITY OF LIFE

The Israel Cancer Research Fund (ICRF) is a voluntary charitable organization that receives its total income from private donations. Its main goals are the advancement of cancer research and the training of Israeli scientists in Israel. To that end, funds for cancer research are available to citizens of Israel, both native-born and those who have settled. Funds are not available to visiting scientists. (Proof of Israeli citizenship must be furnished upon request.)

For purposes of this grant category only, funds may be requested for basic, clinical or translational research, which must relate to quality of life issues for cancer patients (with an emphasis on non-opioid solutions) and must be conducted, in whole or in part, in Israel.

Information on applying for ICRF research grants can be downloaded from our website, or obtained from the address above. For any questions or problems, please send an E-mail message to: ellen.rubin@icrfny.org.

**BEFORE ANY APPLICATION WILL BE PROCESSED OR REVIEWED, ALL OF THE REQUIRED ITEMS MUST BE COMPLETED EXACTLY AS REQUESTED; OTHERWISE THE APPLICATION WILL BE RETURNED AUTOMATICALLY AND NOT REVIEWED.**

### Timetable for the Awarding of Grants

<i>RECEIVED BY THE FUND IN NEW YORK</i>	<i>NOTIFICATION OF DECISION</i>	<i>ACTIVATION OF AWARD</i>
January 17, 2018	July 1, 2018	September 1, 2018

### Purpose

Quality of Life care is care given to improve the life of patients who have a serious or life-threatening disease, such as cancer. The goal of Quality of Life care is to prevent or treat, as early as possible, the symptoms and side effects of the disease and its treatment, in addition to the related psychological, social, and spiritual problems. Quality of Life care is given throughout a patient's experience with cancer. It should begin at diagnosis and continue through treatment, follow-up care, and the end of life. However, most treatment regimens focus on opioid medications, which are effective, but have problematic side effects.

Graciously supported by the Brause Family, this special ICRF research grant initiative has been established to improve and increase quality of life alternatives for cancer patients. These grants are intended to support the research of established investigators. Grants will be made to an Israeli institution or collaborating institutions with the understanding that they will support a specific research project under the direction of a designated principal investigator studying the treatment of pain, side effects, and emotional problems experienced by cancer patients in order to maintain the best possible quality of life, with an emphasis on non-opioid solutions.

Often, quality of life care specialists work as part of a multidisciplinary team to coordinate care. While not a requirement, grants that utilize interdisciplinary approaches and that are multi-investigator are encouraged. International Collaboration is acceptable. However, the principal investigator must be located in Israel, while the collaborating investigator(s) may be located in, and citizens of, North America. The support to the participating institutions will be divided such that 80% of the funds will be designated for the Israeli investigator(s) and institution, and 20% for the investigator(s) in North America. For the North American partners, it would be prudent to ensure that their institutions will accept ICRF grant funds with no indirect costs appended or at most with indirect costs at 10%.

### **Scientific Review of Applications**

Applications will be considered for funding on the basis of the overall merit of the proposal as determined by the Scientific Review Panel, relevance of the proposal to the research objectives of the ICRF and this special program, and the availability of funds. They will be reviewed as a special category by a separate Scientific Review Panel.

Acting upon the recommendations of this special Scientific Review Panel, as well as the International Scientific Council, the Board of Trustees of the ICRF then approves all awards.

### **Eligibility**

ICRF Quality of Life Grants are intended to support the research of established investigators. The application must originate from an Israeli scientist/institution, who will be designated as the principal investigator. All additional collaborating investigators/institutions, whether in Israel or in North America, will be considered as co-investigators. The Israeli institutions are not permitted to utilize ICRF funds for overhead or other indirect costs. While the ICRF would prefer that the North American institutions do the same, we will only allow a maximum of 10% for indirect costs.

### **Duration and Amount of the Award**

Awarded grants will be for a period of three (3) years, at a total stipend of \$250,000 (approximately \$83,333 per year). It is anticipated that up to four grants will be awarded. Funding for the second and third years will be contingent upon acceptable progress during years one and two of the grant, as evidenced in a short report due annually.

***ONLY ONE (1) GRANT APPLICATION PER PRINCIPAL INVESTIGATOR  
WILL BE ACCEPTED FOR EACH SUBMISSION DEADLINE***

### **Fiscal Requirements for Institution**

A separate account must be maintained for each award. This account must be available for audit at any time by representatives of the ICRF. A report of these expenditures, detailing the utilization of the funds (salaries, supplies, etc.), must be submitted to ICRF semi-annually. Forms will be sent directly to the institution by the ICRF office. Grant payments will be suspended, if these reports become overdue.

### **Special Leave**

- A. Special leave for the Israeli PI for work in another institution (with continuing support from the award) may be permitted, if directly related to the purpose of the award. Normally, such leave shall not exceed three months. For a longer period, prior approval of the ICRF is required. To obtain approval, the awardee must submit to the ICRF at least six (6) months prior to the leave, a letter describing the plan, and how the awardee will supervise his/her laboratory during this period. This letter must be countersigned by the awardee's department head and the appropriate institutional official. Such leave may not exceed twelve (12) months.
- B. Leave without award support requires the prior approval of the ICRF and will be granted only in unusual situations. Such leave may not exceed twelve (12) months. Support from other sources is permissible during the period of leave, and such leave does not reduce the total number of months of program support for which an awardee is eligible.

### **Special Conditions**

Should the ICRF awardee(s) or the sponsoring institution(s) specified by our award vacate the project, the ICRF will automatically void the award and terminate funding. Failure of the institution(s) to notify the ICRF of such vacancy will allow the ICRF to recover funds *in toto*.

### **Change of Institution**

1. A letter of request to ICRF for permission to transfer the award to another eligible institution must be received by ICRF at least six (6) months prior to moving. This letter should include the name of the new institution, as well as assurance of continuation of the awarded project.
2. A letter of acceptance from the new institution and a letter of release from the original institution. Additionally, the original institution will be required to submit a final report of expenditures, and any unexpended funds must either be returned to the ICRF or transferred to the new institution.
3. A description of the new work facilities. (Please refer to Section II - Instructions, No. 17.)

If a request is not received at least six (6) months prior to the move, the ICRF reserves the right to automatically void the award and terminate funding.

### **Continuation of Awards**

1. Annual progress reports from each institution will be required before release of subsequent year funding. A reminder notice with instructions and cover sheet will be sent out in advance of the due date. This cover sheet must be attached to the report.
2. A financial report from each institution involved detailing the allocation of funds received to the date of the renewal request will also be required. Forms will be sent directly to the institution by the ICRF office. (In general, financial reports are required semi-annually.)

Award renewal is not automatic upon receipt of new documents. Renewal requires the approval of the ICRF Scientific Review Panel.

### **Biohazards and Protection of Human Subjects/Animals**

Safeguarding the rights and welfare of human subjects involved in activities supported by the ICRF, as well as consideration of potential biohazards, is the responsibility of the institution that received the award. Awards for projects involving human subjects and/or animals require prior review and approval by the appropriate institutional committee. Such written approvals must be submitted along with the ICRF application. The review date should be recent; certification is invalid if the review date precedes the submission date by more than one year. These approval letters must be written *in English*.

### **Publications**

Publications resulting from projects supported by the Fund must contain the following acknowledgment:

*"This study was supported by a Brause Family Initiative for Quality of Life Grant from the Israel Cancer Research Fund."*

Awardees should send electronic copies of publications carrying the above credit line to the ICRF International Executive Office in New York as soon as possible after publication.

### **Patents**

No patent application for work done under an ICRF award shall be filed by the grantee institution or by any individual investigator engaged in this research without prior consultation with and written approval of the Fund.

### **Changes and Amendments**

Any changes or amendments to the original award must be approved in writing by the Fund.

**###**